| Inclusion Criteria: | 1) All patients must have either surface CD3+ T-cell malignant diseases diagnosed by morphologic, histochemical or cell surface marker criteria. Patients with T-ALL must have surface CD3 on at least 80% of the lymphoblasts as determined by flow cytometry.
2) Patients with CD3+ T-cell malignant diseases must have failed or be refractory to approved therapeutic agents or choose to decline or defer, after adequate informed consent, clinically meaningful palliative therapy.
3) Age >/= 18 years.
4) Patients >/= 12 years of age with CD3+ T-cell malignant diseases must have failed or be refractory to approved therapeutic agents [applies only for subjects enrolled at Texas Children' Hospital].
5) Patients >/= 12 years may be accrued beginning at dose level 2.5 mcg/kg.[applies only for subjects enrolled at Texas Children' Hospital].
6) Patients must have a performance status of </= 2 on Eastern Cooperative Oncology Group scale. Patients must have fully recovered from toxicity of prior chemotherapy or radiation therapy.
7) Patients must have bilirubin </= 1.5 mg/dL, transaminases < 2.5 X ULN, albumin >/= 3 gm/dL, creatinine </= 2.0 mg/dL, adequate pulmonary function by physical exam and pulse oxometry and adequate cardiac reserve (EF >/= 50% normal).
8) Pre-treatment anti-A-dmDT390-bisFv (UCHT1) level is </= 3 micrograms/mL.
9) Patients must give written informed consent prior to registration.
10) Females and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion. |